Processa Pharmaceuticals (PCSA) Tax Provisions (2012 - 2021)
Processa Pharmaceuticals' (PCSA) quarterly Tax Provisions came in at -$181752.0 in Q4 2021, up 74.57% on a YoY basis from -$104116.6 in Q4 2020, and down 48.44% quarter-over-quarter from -$122442.0 in Q3 2021.
Powered by 
Analysis
Processa Pharmaceuticals (PCSA) Tax Provisions (2012 - 2021) Analysis & Trends
Processa Pharmaceuticals (PCSA) has reported Tax Provisions for 8 consecutive years, with -$181752.0 the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Tax Provisions rose 74.57% year-over-year to -$181752.0; the trailing twelve-month figure through Dec 2021 stood at -$530611.0 (up 46.99% YoY), and the FY2025 full-year result was -$2.8 million, down 14.46% from the prior year.
- Tax Provisions declined to -$181752.0 in Q4 2021 per PCSA's latest filing, from -$122442.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $260514.0 in Q4 2017 and bottomed at -$714598.0 in Q4 2020.
- Historically, Tax Provisions has averaged -$154364.7 across 5 years, with a median of -$134319.0 in 2018.
- The sharpest annual moves came in 2018 and 2021: Tax Provisions sank 10879.54% in 2018, then surged 74.57% in 2021.
- Over 5 years, Tax Provisions stood at $260514.0 in 2017, then plunged by 150.47% to -$131469.0 in 2018, then retreated by 22.13% to -$160564.0 in 2019, then tumbled by 345.05% to -$714598.0 in 2020, then soared by 74.57% to -$181752.0 in 2021.
- According to Business Quant data, Tax Provisions over the past three periods registered -$181752.0, -$122442.0, and -$137169.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 165.91 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 39.70 Mn |
| 10 | Processa Pharmaceuticals | 5.75 Mn | 5.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -181,752.00 |
| Sep 30, 2021 | -122,442.00 |
| Jun 30, 2021 | -137,169.00 |
| Mar 31, 2021 | -89,248.00 |
| Dec 31, 2020 | -714,598.00 |
| Sep 30, 2020 | -70,457.00 |
| Jun 30, 2020 | -87,835.00 |
| Mar 31, 2020 | -128,129.00 |
| Dec 31, 2019 | -160,564.00 |
| Sep 30, 2019 | -141,251.00 |
| Jun 30, 2019 | -170,602.00 |
| Mar 31, 2019 | -130,299.00 |
| Dec 31, 2018 | -131,469.00 |
| Sep 30, 2018 | -212,015.00 |
| Jun 30, 2018 | -277,783.00 |
| Mar 31, 2018 | -281,534.00 |
| Dec 31, 2017 | 260,514.00 |
| Sep 30, 2017 | -1,931.00 |
| Dec 31, 2015 | -25.00 |
| Sep 30, 2015 | -25.00 |